Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22924 | 0.97 | KDM4E (0.37) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL30154994 | 0.94 | KDM4E (0.35) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL4687605 | 0.94 | KDM4E (0.35) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL22492 | 0.94 | KDM4E (0.39) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL4356890 | 0.91 | KDM4E (0.37) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL1652589 | 0.91 | KDM4E (0.37) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL27916861 | 0.91 | KDM4E (0.37) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL536032 | 0.91 | KDM4E (0.37) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| Cyclohexane SCHEMBL28119425 | 0.89 | FDPS (0.32) | KDM4EMMP2THRBMAPK1HSD17B10 | |
| SCHEMBL30699335 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282989-A1 | SCALE INHIBITORS AND RELATED METHODS | LFS CHEMISTRY INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2023220175-A1 | SCALE INHIBITORS AND RELATED METHODS | LFS CHEMISTRY INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282989-A1 | SCALE INHIBITORS AND RELATED METHODS | NUP210, SLC6A19, SLC7A1 | KDM4E 530/4885MMP2 354/4885THRB 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.